apoB: The Number Your Standard Cholesterol Panel Leaves Out

Two people walk out of the lab with the same LDL cholesterol number. One has a heart attack at 58; the other reaches 90 with clean arteries. The standard lipid panel treated them as identical, and it was wrong about at least one of them. The reason is that the panel measures the wrong thing: how much cholesterol your LDL particles are carrying, not how many particles are knocking against your artery walls. A single blood marker, apolipoprotein B (apoB), counts the particles directly. Here is what it measures, what the evidence actually supports, and how to put it to work.

What apoB actually counts

Every atherogenic lipoprotein that can burrow into an artery wall, LDL, VLDL, IDL, and Lp(a), carries exactly one apoB-100 protein on its surface. Count the apoB molecules and you have counted the particles. That is the whole idea.

Standard LDL cholesterol (LDL-C) instead estimates the cargo: the mass of cholesterol those particles carry. The problem is that cholesterol per particle varies from person to person. Someone with many small, cholesterol-poor particles can show a reassuring LDL-C while carrying a high particle burden. It is the difference between weighing the total freight and counting the trucks. Atherosclerosis is driven by the number of particles crossing into the wall, so the count is the more direct read on risk.

apoB has practical advantages too. It is measured by a standardized immunoassay, it is inexpensive, and it does not require fasting because its level barely shifts after a meal (Sniderman and colleagues, Journal of the American Heart Association, 2022).

Established evidence

Causality, not just correlation. Mendelian randomization studies, which use inherited genetic variation to approximate a lifelong randomized trial, point to apoB-carrying particles as a causal driver of atherosclerotic cardiovascular disease, with apoB carrying predictive information beyond LDL-C. The 2017 European Atherosclerosis Society consensus statement pulled genetic, epidemiologic, and trial evidence together to conclude that LDL and related apoB particles cause atherosclerotic disease.

Guidelines already list targets. The 2019 ESC/EAS dyslipidaemia guidelines name apoB as a secondary treatment goal: below 65 mg/dL for very-high-risk people, below 80 for high risk, and below 100 for moderate risk. In 2024 the National Lipid Association published an expert clinical consensus specifically on using apoB in adults, a sign the marker has moved from niche to mainstream.

Discordance is common and it matters. When apoB (or particle number) and LDL-C disagree, outcomes track the particle count. In the Framingham Offspring Study, people with low particle number had 59 cardiovascular events per 1,000 person-years, versus 81 for those with an equivalently low LDL-C (Cromwell and colleagues, 2007). In the Multi-Ethnic Study of Atherosclerosis, LDL-C and particle number were discordant in roughly 44% of participants, and particle number was the better predictor when they diverged.

Emerging evidence

Two adjacent tools are promising but less settled. NMR-measured LDL particle number (LDL-P), the technology Jim Otvos pioneered and the first FDA-cleared direct particle count, tells a story very close to apoB and is often used interchangeably; head-to-head, apoB is cheaper and more standardized, so treat NMR as a useful alternative rather than a clear upgrade. GlycA, an NMR-derived signal of chronic low-grade inflammation, has been linked in cohort studies to cardiovascular events and all-cause mortality, but it is not yet a guideline target and belongs in the "watch this space" column, not the action list.

How to get and read your apoB

1. Ask for it by name. apoB is a standard add-on to a lipid panel at most major labs. No fasting is required, which makes it easy to bundle with routine bloodwork.
2. Measure Lp(a) once. Lp(a) is largely genetic and stable for life, so a single measurement tells you whether it is inflating your particle burden. apoB itself you repeat over time.
3. Read it against your risk tier, using the ESC secondary goals above as anchors: under 65 mg/dL is aggressive, 65 to 80 is a reasonable target for many, and above 100 warrants a conversation with your clinician.
4. Check for discordance. If your LDL-C looks "fine" but your apoB sits high for that LDL-C, believe the apoB. This mismatch is most common in people with high triglycerides, metabolic syndrome, or type 2 diabetes.
5. Retest after any change in diet, training, or medication, at 8 to 12 weeks, so you are comparing particle counts, not guesses.

Mistakes to avoid

• Trusting LDL-C alone when your metabolism is off. High triglycerides, insulin resistance, and diabetes are exactly where LDL-C most often understates particle burden. That is the population that most needs apoB, and the one most often reassured by a normal-looking panel.
• Believing "large, fluffy LDL is harmless." Otvos and others have pushed back on this: particle number, not particle size, is what tracks with events. A high count of large particles is still a high count.
• Chasing HDL up as if it were a treatment target. Trials raising HDL have not delivered the expected event reduction; apoB is the actionable number.
• Confusing a marker with a diagnosis. A high apoB is a risk signal to act on with a clinician, not a verdict, and not something to self-treat.
• Testing once and stopping. apoB earns its value as a trend line you move, not a single snapshot.

A concrete case

Take a 52-year-old with LDL-C of 110 mg/dL, triglycerides of 190, a widening waistline, and a family history of early heart disease. His panel reads "borderline," so nothing changes for years. An apoB drawn at the same visit comes back at 115 mg/dL, well above his risk-tier goal: the small, triglyceride-rich particles hid behind an average LDL-C. That single number reframes the picture and, with his clinician, gets him onto zone 2 training, a lower refined-carbohydrate intake, and a discussion about medication. Same blood draw, very different decision.

Markers that tell you it is working

• apoB in mg/dL, trending down toward your risk-tier target across repeat tests.
• apoB and LDL-C moving into agreement, so the discordance narrows.
• Falling triglycerides alongside apoB, a sign the small-particle load is easing.
• A stable Lp(a) baseline you have measured once and can factor in.

Personal experimentation

This is the part to hold loosely. Some clinicians and self-trackers, Peter Attia among them, argue for pushing apoB well below guideline thresholds, into the 60s or lower, on the logic that lifetime particle exposure drives risk. That is a reasonable hypothesis, but it is beyond what current guidelines formally endorse, so treat any personal target under 65 mg/dL as experimentation to run with a clinician, tracked with repeat labs, not as established fact.

What to do this week

Ask for apoB (and a one-time Lp(a)) the next time you have bloodwork; you do not need to fast. Read the number against your risk tier, and if it disagrees with your LDL-C, trust the particle count and bring it to your clinician. Then retest in 8 to 12 weeks after any change, so you are steering by the marker that actually counts the particles, not the one that weighs them.

Sources